



Biocon: Enhancing Global Healthcare

Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India's largest and fully-integrated, innovation-led biopharmaceutical company. It is globally recognized enterprise serving customers in over 120 countries. Driven by a vision to enhance global healthcare through innovative and affordable biopharmaceuticals, we have enabled access to advanced therapies for diseases that are chronic, where medical needs are largely unmet and treatment costs are high.

We are driven by the belief that the pharmaceuticals industry has a humanitarian responsibility to enable access to essential drugs for patients who are in need and to do so with the power of innovation. In line with this, we have crafted a differentiated product portfolio, which straddles small molecules as well as biologics, both novel as well as biosimilars.

The significant brand equity that we have built worldwide for our small molecule APIs across statins, immunosuppressants and other specialty products has made us a leading global supplier of these products.

We have also built one of the largest and most diverse biosimilar pipelines, spanning insulins, monoclonal antibodies and other recombinant proteins that address critical chronic diseases such as diabetes, cancer and autoimmune disorders.

Among the leading biosimilar players globally for insulins, we are the first Indian company to launch a biosimilar in Japan with Insulin Glargine, which also has been commercialized in Europe. Our insulin products have made a difference to the lives of millions of people with

diabetes across the globe. We now aim to provide our insulin products to 'one in five' people with diabetes in need of insulin-based therapy anywhere in the world.

We are also making a huge impact in the area of cancer care. Our biosimilar Trastuzumab, which was the first to be approved anywhere in the world and launched in India in 2014, has helped treat several thousand HER2-positive metastatic breast cancer patients. We are also the first company from India to get its biosimilar approved by the U.S. Food and Drug Administration; Ogivri®, co-developed by Biocon and Mylan, is the first biosimilar Trastuzumab to be approved in the U.S. Three of our biosimilars co-developed with partner Mylan have been commercialized in developed markets viz. Pegfilgrastim in U.S., Trastuzumab and Insulin Glargine in EU.

We are also developing a pipeline of patented biologics to address global unmet medical needs. We have successfully launched a couple of novel biologics in India: Nimotuzumab for the treatment of head and neck cancer and Itolizumab to tackle psoriasis. Besides these, we have a basket of novel assets are under various stages of clinical development, including a high potential oral insulin.

Through our subsidiary, Syngene, we offer high-end, fully integrated scientific research services that drive innovation, deliver greater efficiency and ensure value creation for clients in the global life sciences sector.

Ranked by the prestigious Science magazine among the Top 10 Best employers in the biotech industry, Biocon is passionately pursuing a mission to rationalize healthcare spends, enhance access to life-saving therapies and make a significant impact to global healthcare through 'blockbuster' drugs with the potential to benefit a billion patients.